These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 34855241)
1. Treatment of metastatic cutaneous squamous cell carcinoma in a solid organ transplant recipient with programmed death-1 checkpoint inhibitor therapy. O'Connell KA; Schmults CD J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():45-48. PubMed ID: 34855241 [TBL] [Abstract][Full Text] [Related]
2. A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma. Tsung I; Worden FP; Fontana RJ Oncologist; 2021 Feb; 26(2):133-138. PubMed ID: 32969143 [TBL] [Abstract][Full Text] [Related]
3. Rapid Life-Saving Response to Anti-PD-1 in a Solid Organ Transplant Recipient With Metastatic Cutaneous Squamous Cell Carcinoma: A Case Report and Review. Antonelli JP; Quach M; Mahajan A; Pleva J; Ma VT J Immunother; 2024 Jul-Aug 01; 47(6):216-219. PubMed ID: 38532708 [TBL] [Abstract][Full Text] [Related]
4. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699 [TBL] [Abstract][Full Text] [Related]
5. Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients. Van Meerhaeghe T; Baurain JF; Bechter O; Orte Cano C; Del Marmol V; Devresse A; Doubel P; Hanssens M; Hellemans R; Lienard D; Rutten A; Sprangers B; Le Moine A; Aspeslagh S Front Nephrol; 2022; 2():1041819. PubMed ID: 37675002 [TBL] [Abstract][Full Text] [Related]
6. Prompt response of advanced cutaneous squamous cell carcinoma to cemiplimab in a kidney transplant patient receiving treatment with everolimus. Gambichler T; Hessam S; Lüttringhaus T; Boms S Clin Exp Dermatol; 2022 Mar; 47(3):608-609. PubMed ID: 34767651 [TBL] [Abstract][Full Text] [Related]
7. Durable complete response to early immunotherapy discontinuation in a kidney transplant recipient with advanced cutaneous squamous cell carcinoma: A case report and review of literature. Lu Z; Afzal M; Shirai K Transpl Immunol; 2023 Dec; 81():101932. PubMed ID: 37734447 [TBL] [Abstract][Full Text] [Related]
8. Systematic review of programmed cell death-1 inhibitor therapy for advanced-stage cutaneous squamous cell carcinoma in solid-organ transplant recipients. Hanania HL; Lewis DJ J Dermatolog Treat; 2022 Dec; 33(8):3119-3126. PubMed ID: 36018250 [TBL] [Abstract][Full Text] [Related]
9. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma. Benzaquen M Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547 [TBL] [Abstract][Full Text] [Related]
10. A case controlled study of risk factors for metastatic squamous cell carcinoma in organ transplant recipients: single academic medical center. Griffith CF; Solhjoo A; Mahan L; Nijhawan RI Arch Dermatol Res; 2024 Sep; 316(8):612. PubMed ID: 39259378 [TBL] [Abstract][Full Text] [Related]
11. Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection. Lipson EJ; Naqvi FF; Loss MJ; Schollenberger MD; Pardoll DM; Moore J; Brennan DC Am J Transplant; 2020 Aug; 20(8):2264-2268. PubMed ID: 32185872 [TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers-Emerging Strategies for Clinical Management. Ferrándiz-Pulido C; Leiter U; Harwood C; Proby CM; Guthoff M; Scheel CH; Westhoff TH; Bouwes Bavinck JN; Meyer T; Nägeli MC; Del Marmol V; Lebbé C; Geusau A Transplantation; 2023 Jul; 107(7):1452-1462. PubMed ID: 36706163 [TBL] [Abstract][Full Text] [Related]
13. Cemiplimab for Locally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series of 3 Unique Scenarios. Akhtar K; Sravanthi MV; D'Angelo J; Sivapiragasam A J Investig Med High Impact Case Rep; 2022; 10():23247096221121408. PubMed ID: 36017984 [TBL] [Abstract][Full Text] [Related]
14. Solid organ transplantation worsens the prognosis of patients with cutaneous squamous cell carcinoma of the head and neck region-Comparison between solid organ transplant recipients and immunocompetent patients. Ritter A; Badir S; Mansour M; Segal Z; Ad-El D; Bachar G; Shpitzer T; Popovtzer A; Mizrachi A Head Neck; 2021 Mar; 43(3):884-894. PubMed ID: 33247523 [TBL] [Abstract][Full Text] [Related]
15. Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient. Vidovic D; Simms GA; Pasternak S; Walsh M; Peltekian K; Stein J; Helyer LK; Giacomantonio CA Front Immunol; 2021; 12():678028. PubMed ID: 34122442 [TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review. Portuguese AJ; Tykodi SS; Blosser CD; Gooley TA; Thompson JA; Hall ET J Natl Compr Canc Netw; 2022 Apr; 20(4):406-416.e11. PubMed ID: 35390767 [TBL] [Abstract][Full Text] [Related]
17. Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp. Paoluzzi L; Ow TJ Curr Oncol; 2021 Jan; 28(1):574-580. PubMed ID: 33477979 [TBL] [Abstract][Full Text] [Related]
18. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel. Lebas E; Marchal N; Rorive A; Nikkels AF Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680 [TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis. Owoyemi I; Vaughan LE; Costello CM; Thongprayoon C; Markovic SN; Herrmann J; Otley CC; Taner T; Mangold AR; Leung N; Herrmann SM; Kukla A Cancer; 2020 Nov; 126(21):4780-4787. PubMed ID: 32786022 [TBL] [Abstract][Full Text] [Related]